Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 24, 2021
Discovery & Translation

New mechanisms and modalities emerge for TIGIT

2021 ASH and SITC abstracts are low on data, high on innovation
BioCentury | Mar 5, 2021
Product Development

March 4 COVID Quick Takes: More guidance on vaccines for variants; plus EMA begins review of Sputnik V, Novartis-CureVac, Bharat-Ocugen, Novavax and more

The ACCESS consortium, a coalition of regulatory authorities from the U.K., Australia, Canada, Singapore and Switzerland, released guidance on Thursday outlining the data needed to approve
BioCentury | Jun 13, 2016
Company News

Kyowa Hakko Kirin, Medgenics deal

BioCentury | Mar 18, 2013
Strategy

Japan's biggest biotech

KHK's scientist-CEO expanding beyond Japan with in-house tech, academic targets
BioCentury | May 5, 2011
Cover Story

LIGHTs out for asthma

BioCentury | Apr 28, 2011
Distillery Therapeutics

Indication: Inflammation

BioCentury | May 18, 2009
Company News

Kyowa Hakko Kirin, sanofi-aventis deal

BioCentury | May 15, 2009
Company News

sanofi-aventis licenses Kyowa mAb

Items per page:
1 - 10 of 10